Tim Smith

A recent research letter highlighted the importance of diversity in the field of dermatology, citing the lack of diversity among trainees in the field.

New trial data presented at ACAAI 2022 suggest a potential insight into treating chronic spontaneous urticaria after a period of omalizumab treatment.

Phase 3 trial data from the INTEGUMENT-1 study yielded positive results for roflumilast cream on atopic dermatitis patients ages 6 and up.

New data presented at ACAAI 2022 observed various trends in allergies associated with eczema and eosinophilic esophagitis, comparing observed data with that of patients in the United States.

Researchers tested the newly-designed Rosacea Area and Severity Index, or RASI, against the Investigator’s Global Assessment tool used to assess rosacea concerns for patients.

In a recent study, patients with plaque psoriasis or vitiligo who were receiving phototherapy were found to have higher rates of skin cancer than the general population.

New research suggests that certain interleukin-17 blockage therapies may not alleviate sleeping issues in patients with psoriasis.

A discussion with Dr. Lal regarding a recent 12-week trial evaluating the use of topical berdazimer gel for molluscum contagiosum.

New research suggests the use of simvastatin treatment may be helpful for patients with nonsegmental vitiligo and dyslipidemia.

A new population-based study demonstrates an association between patients having systemic sclerosis and vitiligo, suggesting both conditions may need to be monitored for comorbidities.

New research indicated that topical 5 FU for patients with vitiligo may be an option that is both a promising and cost-effective treatment for the skin condition.

A recent discussion with Dr. Brown on the use of tapinarof, approved for adult plaque psoriasis, in patients with atopic dermatitis.

A recent study highlighted some information on hidradenitis suppurativa patients and their ongoing care needs after being treated in emergency departments.

In this study, the investigators assessed risk factors in patients with DRESS syndrome receiving vancomycin to treat gram-positive infections.

An analysis of serum dupilumab treatment for atopic dermatitis patients suggests a lack of association between either response or adverse effects.

The FDA recently approved a drug treatment for HBV infection for pediatric patients 12 and older with compensated liver disease.

A recent study into autoimmune and metabolic disturbances identified an association between these conditions and vitiligo cases.

An interview featuring Dr. Rosmarin regarding the recent phase 3 TRuE-V trials on ruxolitinib and nonsegmental vitiligo treatment.

A discussion regarding the main data points from the Phase 3 TRuE-V clinical trial program assessing the use of ruxolitinib cream for nonsegmental vitiligo.

New research demonstrated a correlation between specific VDR polymorphisms and patients’ liability of having vitiligo.

A discussion with the moderator of the Global Parents for Eczema Research symposium regarding climate change and the effects of fire, drought, airborne pollution on atopic dermatitis.

A discussion with Dr. Boos on the topic of climate change and airborne pollution exposure leading to or exacerbating atopic dermatitis.

A discussion with Dr. Lal on the topics of benefits of ruxolitinib treatment for nonsegmental vitiligo, as well as on the recent recall of hair products due to benzene risk.

A recent research letter highlighted a case observed in Japan in which a patient with alopecia totalis, and an associated case of atopic dermatitis, was treated effectively with baricitinib, a JAK inhibitor.

Recent phase 3 trial data suggests the efficacy across multiple endpoints of roflumilast foam as a treatment for seborrheic dermatitis.

New research suggests the sleep quality of caregivers and patients with atopic dermatitis (inadequately-controlled with topical therapies) may improve with dupilumab treatment.

Recent clinical trial data from UNCOVER-1 and UNCOVER-2 demonstrated the positive effects of ixekizumab use in adult plaque psoriasis patients.

During a recent interview regarding ReOpen1 and ReOpen2 trials, Dr. Mahmoud described a new treatment device for chronic rhinosinusitis patients.

The recent GUIDE study examined the efficacy of guselkumab for moderate-to-severe plaque psoriasis, finding it consistent with previous trials.

Recent phase 3 trial results suggest positive effects and faster onset using CAL/BDP cream for adult plaque psoriasis.